Newmark Arranges Lease Renewal for Invivoscribe’s U.S. Headquarters in San Diego’s Sorrento Mesa Submarket

October 9, 2025 9:00 AM

Newmark announces the Company has arranged a renewed U.S. Headquarters lease for Invivoscribe, a global biotechnology company dedicated to improving the standardization of diagnostics and accelerating precision medicine, at 10222 Barnes Canyon Road in San Diego, California. The lease includes 52,477 square feet of specialized life sciences and office space in the heart of the Sorrento Mesa submarket.

Newmark Executive Managing Director John Hundley and Managing Director Jon Engle represented Invivoscribe in the transaction. The lease renewal is among the largest life sciences leases executed in San Diego year-to-date[2], underscoring the market’s continued strength and strategic importance within the national biotech ecosystem.

“This transaction represents the culmination of years of close collaboration and long-term planning,” said Hundley. “From the beginning, we worked to understand Invivoscribe’s evolving operational needs and align them with a real estate strategy that could scale with their growth. This renewal secures a mission-critical headquarters in one of the most competitive life sciences submarkets in the country, with flexibility that enables both stability and innovation for the future.”

The two-story facility combines purpose-built laboratories, cGMP manufacturing space and corporate operations and provides Invivoscribe with long-term operational continuity after nearly a decade of success in this location in San Diego’s fastest-growing submarket. Sorrento Mesa has rapidly emerged as a leading destination for biotech and medtech companies – surpassing even long-established hubs like Torrey Pines in overall growth and activity.

“John and Jon have been trusted partners since 2018, consistently offering data-driven insights and expert guidance throughout our journey,” said Meghna Bhatnagar, Chief Financial Officer of Invivoscribe. “Securing our U.S. Headquarters was a significant milestone, and Newmark played a pivotal role in helping us structure a lease that is both flexible and capital efficient, well-suited for our short- and long-term needs. They advocated assertively on our behalf in negotiations with a large institutional landlord, always with tact and professionalism.”

[1] According to Newmark Research
[2] According to Newmark Research

About Invivoscribe Inc.
Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended June 30, 2025, Newmark generated revenues of over $2.9 billion. As of June 30, 2025, Newmark and its business partners together operated from 165 offices with over 8,400 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.